Sector Alpha Week of 2026-08-05
Sector Alpha — machine-written from the numbers · Data as of 2026-08-05

Eastman Kodak Company

KODK
Industrials · Specialty Business Services

Eastman Kodak Company's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

The sharpest disagreement: profits are rising, but only −45% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.

The price is between stages. Underneath, the last four quarters read improving, and −45% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.

Stage
Deteriorating
fundamental trajectory, 12 quarters
Price
$8.9
+38.4% 1Y
P/E
12.9×
of its own 0-year range
Revenue (Mar 26)
$0.3 B
+8.0% YoY
Profit (Mar 26)
$−0.0 B
Operating margin
0.0%
+4.0 pp YoY
ROE
−13%
FY25
ROIC
27.5%
vs WACC 14.5% → +13.0 pp
Cash conversion
−45%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Eastman Kodak Company trades at $8.9, between stages. That is +2.2% against its own 200-day average. It sits at 37% of a 52-week range of $6 to $14. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (7 weeks and counting).

Today the stock is between stages. At $8.9 it trades +2.2% versus its 200-day average and sits at 37% of its 52-week range ($6–$14).

Aug 26: $8.9 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 1-year window.
+2.2% versus the 200-day line, week — of stage —
Price50-day avg200-day avg
$14.7$12.4$10.0$7.6$5.2$$9$9Jul 25Oct 25Jan 26May 26Aug 26
$14.7$12.4$10.0$7.6$5.2$$9$9Jul 25Jan 26Aug 26
Beating or trailing, week by week since 2025 Each cell is one week from 2025 to now (57 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Jul 25Aug 26

Against the market, two honest reads. Cumulative: over the last 1.1 years the stock moved +33% while the S&P 500 moved +24% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (7 weeks and counting; last ahead the week of 2026-06-18) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Eastman Kodak Company trades at 12.9× P/E, against too little history to rank. Its long-run median P/E is 13.0×, measured across 0.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 12.9× is against too little history to rank, against a long-run median of 13.0× measured over 0.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 12.9× vs a 13.0× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 0.3-year window. The eps (ttm) bars are red where the reading is lower than the quarter before.
against too little history to rank
P/EMedianEPS (TTM) (quarterly)
14.6×$0.513.9×$0.413.2×$0.312.5×$0.111.9×$0.0×$12.94×$1Jul 25Aug 25Sep 25Oct 25Oct 25
14.6×$0.513.9×$0.413.2×$0.312.5×$0.111.9×$0.0×$12.94×$1Jul 25Sep 25Oct 25
PEG 0.21 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Computed here as quarter-end P/E ÷ trailing-twelve-month EPS growth (only quarters with positive growth), because a reported quarterly PEG is not held for this stock. Last 6 quarters.
below 1.0, the growth looks cheap against the multiple
PEGPEG = 1.0
1.1×0.8×0.5×0.3×0.0××0.21×Jun 23Sep 23Dec 23Mar 24Dec 24
1.1×0.8×0.5×0.3×0.0××0.21×Jun 23Dec 23Dec 24
P/E
12.9×
too little history to rank
PEG
n/m
not derivable — 3-year earnings growth unavailable

🚨 Why the multiple sits where it does: over the past year annual EPS moved −297.8% against a +38.4% price move — the price outran earnings, pushing the multiple UP its own range.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Deteriorating

Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Eastman Kodak Company reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −314.3% latest against +700.0% at its 12-quarter best), ROCE holding at 0.0%. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue +2.9% in FY25, profit −230.0% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn. Turnaround-year spikes shown pinned (▲).
Revenue YoYProfit YoYEPS YoY
6.2%348%2.6%174%−1.1%0.0%−4.8%−172%−8.4%−346%%%2.9%−230%FY21FY23FY25
6.2%348%2.6%174%−1.1%0.0%−4.8%−172%−8.4%−346%%%2.9%−230%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Base-effect spikes shown pinned (▲). A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue accelerating
RevenueProfitEPS
4.8%348%1.2%174%−2.3%0.0%−5.8%−174%−9.4%−348%%%3.8%−300%−300%Jun 23Sep 24Mar 26
4.8%348%1.2%174%−2.3%0.0%−5.8%−174%−9.4%−348%%%3.8%−300%−300%Jun 23Sep 24Mar 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
0.1%−0.4%−0.9%−1.4%−1.9%%0%Jun 23Dec 23Sep 24Jun 25Mar 26
0.1%−0.4%−0.9%−1.4%−1.9%%0%Jun 23Sep 24Mar 26
Revenue growth
Stuck low
latest +3.8% · span −8.4% to +3.8%
Profit growth
Falling
latest −314.3% · span −314.3% to +700.0%
EPS growth
Falling
latest −483.7% · span −483.7% to +650.2%
ROCE
Stuck low
latest 0.0% · span −1.8%–0.0%

🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+2.9%−4.0%
Stock price+38.4%
Revenue YoY (Mar 26)
+8.0%
latest quarter vs a year ago
Revenue 10y
−1.8%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

47.3/100 — rank 17 of 30 in Specialty Business Services · 58% evidence confidence

Eastman Kodak Company scores 47.3 out of 100 against the 30 companies it is compared with in Specialty Business Services, ranking 17. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 20.6 + 6.8 + 11.3 + 8.6 = 47.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Eastman Kodak Company reported $0.3 B of revenue in the Mar 26 quarter, +8.0% year on year. That is the 3rd straight quarter of year-on-year growth. Over 4 years it has compounded at −1.8% a year. The last full year, FY25, came in at $1.1 B. The last four reported quarters add to $1.1 B.

FY25 revenue came in at $1.1 B (+2.9% on the year), capping 4 years at −1.8% compound. The latest quarter (Mar 26) printed $0.3 B, +8.0% year on year — the 3rd consecutive quarter of year-over-year growth.

FY25 revenue $1.1 B (+2.9% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
−1.8% a year over 4 years
RevenueYoY growth
1.36.2%1.02.6%0.7−1.1%0.3−4.8%0.0−8.4%$ B%$1B2.9%FY21FY23FY25
1.36.2%1.02.6%0.7−1.1%0.3−4.8%0.0−8.4%$ B%$1B2.9%FY21FY23FY25
Mar 26: $0.3 B (+8.0% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
3rd straight quarter of growth
Revenue (quarterly)YoY growth
0.319.5%0.234.1%0.16−1.3%0.08−6.8%0.00−12%$ B%$0B8%Jun 23Sep 24Mar 26
0.319.5%0.234.1%0.16−1.3%0.08−6.8%0.00−12%$ B%$0B8%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged +3.9% growth against the decade's −1.8% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +3.8% over the last 4 quarters against +0.0%/yr over the last 8 — accelerating.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Eastman Kodak Company's operating margin is 0.0% in the Mar 26 quarter, +4.0 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −4.3% to 0.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 0.0%, +4.0 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −4.3%–0.0%.

Why the margin moved: operating margin went +4.0 pp year on year while gross margin went +2.2 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY25: 0.0% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a −4.3–0.0% band over 5 years
operating marginYoY change (pp)
0.3%2.8%−0.9%1.8%−2.2%0.8%−3.4%−0.3%−4.6%−1.3%%%0%1%FY21FY23FY25
0.3%2.8%−0.9%1.8%−2.2%0.8%−3.4%−0.3%−4.6%−1.3%%%0%1%FY21FY23FY25
Mar 26: 0.0% operating margin (+4.0 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
8.3%13%5.0%7.2%1.7%1.6%−1.6%−4.0%−4.9%−9.5%%%0%4%Jun 23Sep 24Mar 26
8.3%13%5.0%7.2%1.7%1.6%−1.6%−4.0%−4.9%−9.5%%%0%4%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Eastman Kodak Company posted a net loss of $0.02 B in the Mar 26 quarter. The full FY25 year was a loss of $0.1 B. That loss is 7.4% of the quarter's revenue. The same quarter a year earlier lost $0.01 B. 4 of the last 12 reported quarters were loss-making.

Mar 26 profit was $−0.0 B, null year on year. On the full year, FY25 printed $−0.1 B (−230.0%).

FY25 profit $−0.1 B (−230.0% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
Net profitYoY growth
0.12162%0.0557%−0.02−48%−0.08−154%−0.15−259%$ B%$−0B−230%FY21FY23FY25
0.12162%0.0557%−0.02−48%−0.08−154%−0.15−259%$ B%$−0B−230%FY21FY23FY25
Mar 26: $−0.0 B (null YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
0.05253%0.0160%−0.03−133%−0.08−327%−0.12−520%$ B%$0B−466.7%Jun 23Sep 24Mar 26
0.05253%0.0160%−0.03−133%−0.08−327%−0.12−520%$ B%$0B−466.7%Jun 23Sep 24Mar 26

Pace comparison, last four quarters: profit −238.9% vs revenue +3.9%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years −45% of Eastman Kodak Company's reported profit arrived as operating cash — a gap worth watching. In FY25 that was $0.5 B of operating cash against $−0.1 B of profit. After $0.0 B of capital spending, $0.5 B was left as free cash.

FY25: operating cash of $0.5 B against reported profit of $−0.1 B, leaving free cash of $0.5 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is −45% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $0.5 B vs profit $−0.1 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
−45% of 3-year profit arrived as cash
Operating cashNet profitFree cash
0.50.30.20.0−0.2$ B$1B$−0B$1BFY21FY23FY25
0.50.30.20.0−0.2$ B$1B$−0B$1BFY21FY23FY25
Mar 26: operating cash $−0.0 B Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
0.5224%0.4137%0.250%0.1−37%−0.1−124%$ B%$0B200%Jun 23Sep 24Mar 26
0.5224%0.4137%0.250%0.1−37%−0.1−124%$ B%$0B200%Jun 23Sep 24Mar 26

🚨 Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Eastman Kodak Company does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $0.0 B over the last 3 fiscal years.

FY25: capex $0.0 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
0.060.050.030.020.00$ B$0BFY21FY23FY25
0.060.050.030.020.00$ B$0BFY21FY23FY25
Mar 26: capex $0.0 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
0.0220.50.0160.40.0110.20.0050.10.000−0.1$ B$ B$0B$0BJun 23Sep 24Mar 26
0.0220.50.0160.40.0110.20.0050.10.000−0.1$ B$ B$0B$0BJun 23Sep 24Mar 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Eastman Kodak Company earns a ROE of −18% in FY25. Return on invested capital clears the cost of that capital by +13.0 percentage points, so growth here adds value rather than only size. The wiring behind it is −12.1% net margin on 0.66× asset turns.

FY25 ROE is −18%.

Why the return is what it is — the wiring (FY25): −12.1% net margin × 0.66× asset turns × 2.28× balance-sheet leverage ≈ −18.2% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 27.5% − 14.5% = a +13.0 pp spread. The 14.5% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.

FY25: ROE −18% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 14.5% cost of capital used on this page.
the full ladder
ROEROIC (annual)WACC
17%7.6%−1.9%−11%−21%%−18.3%0%FY21FY23FY25
17%7.6%−1.9%−11%−21%%−18.3%0%FY21FY23FY25
Mar 26: ROIC −0.2% (TTM) vs WACC 14.5% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
17%7.8%−1.4%−11%−20%%−0.2%−17.3%Jun 23Sep 24Mar 26
17%7.8%−1.4%−11%−20%%−0.2%−17.3%Jun 23Sep 24Mar 26
11 · Dividend

Dividend

Eastman Kodak Company pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

Eastman Kodak Company does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Eastman Kodak Company carries total debt of $0.3 B against shareholder equity of $0.7 B as of Mar 26, a debt-to-equity of 0.37. On the annual view that ratio went from 0.32 in FY21 to 0.35 in FY25. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of $0.3 B against shareholder equity of $0.7 B — a debt-to-equity of 0.37. On the annual view, debt-to-equity went from 0.32 (FY21) to 0.35 (FY25). Read the returns on this page with that leverage in mind.

FY25: debt $0.3 B at 0.35× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
0.50.60×0.40.52×0.30.43×0.10.35×0.00.27×$ B×$0B0.35×FY21FY23FY25
0.50.60×0.40.52×0.30.43×0.10.35×0.00.27×$ B×$0B0.35×FY21FY23FY25
Mar 26: debt $0.3 B, debt-to-equity 0.37 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
1.11.4×0.91.1×0.60.8×0.30.5×0.00.2×$ B×$0B0.37×Jun 23Sep 24Mar 26
1.11.4×0.91.1×0.60.8×0.30.5×0.00.2×$ B×$0B0.37×Jun 23Sep 24Mar 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

9.6% of Eastman Kodak Company's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 7.4 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 9.6% of the float is sold short, and at typical trading volumes it would take about 7.4 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
9.6%
of the tradable float
Days to cover
7.4
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Eastman Kodak Company: the Z-score reads 1.31. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits inside the distress zone. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

🚨 Why it matters: a Z-score of 1.31 is inside the distress zone — the balance sheet is a real risk, not a detail.

The safety line in one sentence: the Z-score reads 1.31.

15 · Related companies · Specialty Business Services
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1First Advantage CorporationFA 61.8/100Mixed-positive evidence64% evidence LEADER 24.6/35 Revenue 53.4% · PAT — · OPM change 6.6 pp 62% evidence 9.5/25 ROCE 0.9% · OPM 8.7% 76% evidence 8.5/20 P/E 294× · PEG — 15% evidence 19.2/20 RS sector 19.9% · RS bench 26% · 1Y 24.1%12 of 12 weeks ahead 100% evidence
Exact sum: 24.6 + 9.5 + 8.5 + 19.2 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
2ABM Industries IncorporatedABM 60.4/100Mixed-positive evidence85% evidence BREAKING OUT 22.3/35 Revenue 6.5% · PAT 100% · OPM change -0.1 pp 95% evidence 11.4/25 ROCE 2.1% · OPM 3.8% 76% evidence 15.0/20 P/E 15.7× · PEG 0.38 65% evidence 11.7/20 RS sector -4.5% · RS bench 0.4% · 1Y 3%6 of 12 weeks ahead 100% evidence
Exact sum: 22.3 + 11.4 + 15 + 11.7 = 60.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3AramarkARMK 59.2/100Thin evidence · provisional58% evidence LEADER 20.0/35 Revenue — · PAT — · OPM change 0.6 pp 45% evidence 12.4/25 ROCE 2.1% · OPM 4.5% 76% evidence 9.7/20 P/E 32× · PEG — 15% evidence 17.1/20 RS sector 11% · RS bench 16.6% · 1Y 41.9%12 of 12 weeks ahead 100% evidence
Exact sum: 20 + 12.4 + 9.7 + 17.1 = 59.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
4Cintas CorporationCTAS 57.1/100Thin evidence · provisional58% evidence TURNING 20.2/35 Revenue — · PAT — · OPM change -0.2 pp 45% evidence 17.1/25 ROCE 8.4% · OPM 23.2% 76% evidence 9.6/20 P/E 34.9× · PEG — 15% evidence 10.2/20 RS sector -8.3% · RS bench -3.5% · 1Y -10%4 of 12 weeks ahead 100% evidence
Exact sum: 20.2 + 17.1 + 9.6 + 10.2 = 57.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
5AZZ Inc.AZZ 55.2/100Mixed-positive evidence85% evidence ASLEEP 18.6/35 Revenue 5.7% · PAT -23.9% · OPM change 0.7 pp 95% evidence 13.8/25 ROCE 3.9% · OPM 17.2% 76% evidence 10.7/20 P/E 20.7× · PEG 1.43 65% evidence 12.1/20 RS sector 4.6% · RS bench 9.9% · 1Y 38.5%4 of 12 weeks ahead 100% evidence
Exact sum: 18.6 + 13.8 + 10.7 + 12.1 = 55.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6Quad/Graphics, Inc.QUAD 54.7/100Thin evidence · provisional52% evidence BREAKING OUT 17.3/35 Revenue — · PAT — · OPM change -0.1 pp 45% evidence 9.3/25 ROCE 2.2% · OPM 3% 76% evidence 11.1/20 P/E 13.4× · PEG — 15% evidence 17.0/20 RS sector 31.4% · RS bench 37.8% · 1Y 69.3%5 of 12 weeks ahead 70% evidence
Exact sum: 17.3 + 9.3 + 11.1 + 17 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
7CBIZ, Inc.CBZ 53.6/100Thin evidence · provisional58% evidence BREAKING OUT 14.3/35 Revenue — · PAT — · OPM change -0.7 pp 45% evidence 10.7/25 ROCE 0.8% · OPM 23.2% 76% evidence 10.9/20 P/E 15× · PEG — 15% evidence 17.7/20 RS sector 8.2% · RS bench 14% · 1Y -12.8%10 of 12 weeks ahead 100% evidence
Exact sum: 14.3 + 10.7 + 10.9 + 17.7 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
8Maximus, Inc.MMS 52.2/100Mixed-positive evidence81% evidence BASING 18.8/35 Revenue -1.5% · PAT 23.9% · OPM change 0.2 pp 83% evidence 14.3/25 ROCE 4.2% · OPM 11.4% 76% evidence 16.4/20 P/E 9.6× · PEG 0.29 65% evidence 2.7/20 RS sector -29.4% · RS bench -25.6% · 1Y -22.2%0 of 12 weeks ahead 100% evidence
Exact sum: 18.8 + 14.3 + 16.4 + 2.7 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Cimpress plcCMPR 51.2/100Thin evidence · provisional58% evidence LEADER 16.3/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence 11.2/25 ROCE 4.9% · OPM 5.5% 76% evidence 9.9/20 P/E 26.8× · PEG — 15% evidence 13.8/20 RS sector 14.3% · RS bench 20% · 1Y 85.6%11 of 12 weeks ahead 100% evidence
Exact sum: 16.3 + 11.2 + 9.9 + 13.8 = 51.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
10Global Payments Inc.GPN 49.8/100Mixed-negative evidence81% evidence BREAKING OUT 12.9/35 Revenue 14.8% · PAT -55.2% · OPM change -20.9 pp 83% evidence 7.7/25 ROCE 0% · OPM -0.5% 76% evidence 15.6/20 P/E 13.4× · PEG 0.34 65% evidence 13.6/20 RS sector -2.2% · RS bench 3% · 1Y 9%5 of 12 weeks ahead 100% evidence
Exact sum: 12.9 + 7.7 + 15.6 + 13.6 = 49.8 · Decision use: Price leads the evidence: RS versus the benchmark is 3%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
11RB Global, Inc.RBA 48.9/100Mixed-negative evidence81% evidence TURNING 21.1/35 Revenue 9.5% · PAT 7.3% · OPM change 0.5 pp 83% evidence 15.7/25 ROCE 7.5% · OPM 17.6% 76% evidence 4.3/20 P/E 44.1× · PEG 7.47 65% evidence 7.8/20 RS sector -11% · RS bench -6.4% · 1Y -2.7%1 of 12 weeks ahead 100% evidence
Exact sum: 21.1 + 15.7 + 4.3 + 7.8 = 48.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12Cass Information Systems, Inc.CASS 48.9/100Thin evidence · provisional58% evidence BREAKING OUT 17.2/35 Revenue — · PAT — · OPM change -7.1 pp 45% evidence 4.4/25 ROCE -3.2% · OPM -37% 76% evidence 10.7/20 P/E 18.5× · PEG — 15% evidence 16.6/20 RS sector 8.5% · RS bench 14% · 1Y 38.3%4 of 12 weeks ahead 100% evidence
Exact sum: 17.2 + 4.4 + 10.7 + 16.6 = 48.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
13UniFirst CorporationUNF 47.8/100Mixed-negative evidence85% evidence TURNING 10.7/35 Revenue 1.4% · PAT -24.3% · OPM change -4.3 pp 95% evidence 10.4/25 ROCE 0.9% · OPM 3.6% 76% evidence 11.3/20 P/E 41.9× · PEG 1.23 65% evidence 15.4/20 RS sector 13.1% · RS bench 18.6% · 1Y 68.7%4 of 12 weeks ahead 100% evidence
Exact sum: 10.7 + 10.4 + 11.3 + 15.4 = 47.8 · Decision use: Price leads the evidence: RS versus the benchmark is 18.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
14UL Solutions Inc.ULS 47.3/100Mixed-negative evidence81% evidence ASLEEP 23.7/35 Revenue 6.9% · PAT 4.2% · OPM change 2.7 pp 83% evidence 16.2/25 ROCE 6.7% · OPM 18.2% 76% evidence 4.9/20 P/E 50.1× · PEG 4 65% evidence 2.5/20 RS sector -18.4% · RS bench -14.2% · 1Y 17.6%3 of 12 weeks ahead 100% evidence
Exact sum: 23.7 + 16.2 + 4.9 + 2.5 = 47.3 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.4% and the one-year return is 17.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth.
15Thomson Reuters CorporationTRI 47.3/100Mixed-negative evidence81% evidence TURNING 18.9/35 Revenue 5.4% · PAT -25.9% · OPM change 1 pp 83% evidence 16.0/25 ROCE 4.3% · OPM 30.6% 76% evidence 5.5/20 P/E 26.6× · PEG 4.61 65% evidence 6.9/20 RS sector -22.7% · RS bench -18.5% · 1Y -40.3%1 of 12 weeks ahead 100% evidence
Exact sum: 18.9 + 16 + 5.5 + 6.9 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16Dolby Laboratories, Inc.DLB 47.3/100Thin evidence · provisional58% evidence TURNING 16.6/35 Revenue — · PAT — · OPM change -0.7 pp 45% evidence 13.6/25 ROCE 1.2% · OPM 28.5% 76% evidence 10.2/20 P/E 22.8× · PEG — 15% evidence 6.9/20 RS sector -17.4% · RS bench -13% · 1Y -15.6%0 of 12 weeks ahead 100% evidence
Exact sum: 16.6 + 13.6 + 10.2 + 6.9 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
17Eastman Kodak Companythis pageKODK 47.3/100Thin evidence · provisional58% evidence ASLEEP 20.6/35 Revenue 4.4% · PAT -317.5% · OPM change 4.9 pp 62% evidence 6.8/25 ROCE -0.1% · OPM -0.4% 76% evidence 11.3/20 P/E 12.9× · PEG — 15% evidence 8.6/20 RS sector -7.4% · RS bench -2.8% · 1Y 26.8%4 of 12 weeks ahead 70% evidence
Exact sum: 20.6 + 6.8 + 11.3 + 8.6 = 47.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
18Transcat, Inc.TRNS 47.0/100Mixed-negative evidence75% evidence TURNING 12.8/35 Revenue 18.6% · PAT -61.5% · OPM change -4.2 pp 83% evidence 10.1/25 ROCE 1.1% · OPM 4.8% 76% evidence 9.7/20 P/E 125.1× · PEG 1.35 65% evidence 14.4/20 RS sector 6% · RS bench 11.4% · 1Y 16.1%8 of 12 weeks ahead 70% evidence
Exact sum: 12.8 + 10.1 + 9.7 + 14.4 = 47 · Decision use: Price leads the evidence: RS versus the benchmark is 11.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
19Copart, Inc.CPRT 41.4/100Mixed-negative evidence85% evidence BASING 16.8/35 Revenue 1.1% · PAT 5% · OPM change 0.2 pp 95% evidence 16.6/25 ROCE 5.2% · OPM 37.5% 76% evidence 6.6/20 P/E 20.6× · PEG 3.47 65% evidence 1.4/20 RS sector -33.8% · RS bench -30.3% · 1Y -36.3%0 of 12 weeks ahead 100% evidence
Exact sum: 16.8 + 16.6 + 6.6 + 1.4 = 41.4 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
20Amentum Holdings, Inc.AMTM 41.2/100Thin evidence · provisional58% evidence BASING 19.8/35 Revenue — · PAT — · OPM change 1.4 pp 45% evidence 9.0/25 ROCE 1.6% · OPM 4.3% 76% evidence 9.2/20 P/E 45.1× · PEG — 15% evidence 3.2/20 RS sector -21.2% · RS bench -17.1% · 1Y -3.9%0 of 12 weeks ahead 100% evidence
Exact sum: 19.8 + 9 + 9.2 + 3.2 = 41.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
21Target Hospitality Corp.TH 37.9/100Mixed-negative evidence64% evidence FADING 9.3/35 Revenue -7.4% · PAT -197.8% · OPM change -18.2 pp 62% evidence 5.6/25 ROCE -2.9% · OPM -19.7% 76% evidence 9.0/20 P/E 71.2× · PEG — 15% evidence 14.0/20 RS sector 25.2% · RS bench 30.9% · 1Y 89.2%10 of 12 weeks ahead 100% evidence
Exact sum: 9.3 + 5.6 + 9 + 14 = 37.9 · Decision use: Price leads the evidence: RS versus the benchmark is 30.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
22LegalZoom.com, Inc.LZ 37.5/100Mixed-negative evidence75% evidence BREAKING OUT 10.3/35 Revenue 12.9% · PAT -60% · OPM change -3.6 pp 83% evidence 8.6/25 ROCE 1.5% · OPM 1.3% 76% evidence 12.0/20 P/E 94.5× · PEG 0.93 65% evidence 6.6/20 RS sector -13.7% · RS bench -9% · 1Y -23.5%6 of 12 weeks ahead 70% evidence
Exact sum: 10.3 + 8.6 + 12 + 6.6 = 37.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23BrightView Holdings, Inc.BV 35.3/100Mixed-negative evidence65% evidence ASLEEP 12.9/35 Revenue 0% · PAT 2.2% · OPM change -1.1 pp 83% evidence 7.5/25 ROCE 0.6% · OPM 2.3% 76% evidence 8.7/20 P/E 103.1× · PEG — 15% evidence 6.2/20 RS sector -14.2% · RS bench -9.8% · 1Y -13.6%6 of 12 weeks ahead 70% evidence
Exact sum: 12.9 + 7.5 + 8.7 + 6.2 = 35.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24Resolute Holdings Management, Inc.RHLD 33.7/100Adverse evidence62% evidence TURNING 10.5/35 Revenue 82.2% · PAT -83.2% · OPM change -26 pp 83% evidence 7.3/25 ROCE -0.2% · OPM -1.4% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 5.9/20 RS sector -16.2% · RS bench -11.9% · 1Y 177.9%2 of 12 weeks ahead 70% evidence
Exact sum: 10.5 + 7.3 + 10 + 5.9 = 33.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25TIC Solutions, Inc.TIC 31.2/100Thin evidence · provisional53% evidence ASLEEP 14.9/35 Revenue — · PAT — · OPM change -2 pp 39% evidence 4.7/25 ROCE -1% · OPM -6% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 1.6/20 RS sector -27.4% · RS bench -23.4% · 1Y -11.3%1 of 12 weeks ahead 100% evidence
Exact sum: 14.9 + 4.7 + 10 + 1.6 = 31.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
26BlackSky Technology Inc.BKSY 29.7/100Thin evidence · provisional55% evidence ASLEEP 9.0/35 Revenue -9.3% · PAT — · OPM change -48.7 pp 62% evidence 3.8/25 ROCE -6.5% · OPM -89.2% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 6.9/20 RS sector -12.6% · RS bench -8.3% · 1Y 48.7%4 of 12 weeks ahead 70% evidence
Exact sum: 9 + 3.8 + 10 + 6.9 = 29.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
27Spire Global, Inc.SPIR 26.7/100Adverse evidence64% evidence ASLEEP 7.1/35 Revenue -36% · PAT — · OPM change -36.7 pp 62% evidence 3.1/25 ROCE -30.4% · OPM -155.2% 76% evidence 11.5/20 P/E 8.3× · PEG — 15% evidence 5.0/20 RS sector -8% · RS bench -3.6% · 1Y 40.4%6 of 12 weeks ahead 100% evidence
Exact sum: 7.1 + 3.1 + 11.5 + 5 = 26.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
28RELX PLCRELX 52.3/100Thin evidence · provisional43% evidence TURNING 18.9/35 Revenue — · PAT — · OPM change — 12% evidence 16.1/25 ROCE 9.3% · OPM — 61% evidence 10.5/20 P/E 19.2× · PEG — 15% evidence 6.8/20 RS sector -18.5% · RS bench -14.2% · 1Y -23.3%1 of 12 weeks ahead 100% evidence
Exact sum: 18.9 + 16.1 + 10.5 + 6.8 = 52.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
29Public Policy Holding Company, Inc.PPHC 44.5/100Thin evidence · provisional11% evidence 17.5/35 Revenue — · PAT — · OPM change — 0% evidence 7.0/25 ROCE -11.5% · OPM — 46% evidence 10.0/20 P/E — · PEG — 0% evidence 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence
Exact sum: 17.5 + 7 + 10 + 10 = 44.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
30Rentokil Initial plcRTO 42.1/100Thin evidence · provisional43% evidence ASLEEP 18.1/35 Revenue — · PAT — · OPM change — 12% evidence 12.7/25 ROCE 1.8% · OPM — 61% evidence 9.8/20 P/E 30.3× · PEG — 15% evidence 1.5/20 RS sector -27% · RS bench -23.2% · 1Y -0.8%0 of 12 weeks ahead 100% evidence
Exact sum: 18.1 + 12.7 + 9.8 + 1.5 = 42.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Eastman Kodak Company's stock price today?

Eastman Kodak Company trades at $8.9, +38.4% over the past year. The company is valued at $1.0 B. The stock sits at 37% of its 52-week range of $6–$14, +2.2% versus its 200-day average. Against the S&P 500 it has been behind on a trailing-13-week view for 7 weeks. — as of 5 August 2026.

What were Eastman Kodak Company's latest quarterly results?

Eastman Kodak Company reported revenue of $0.3 B and a net loss of $0.0 B for the Mar 26 quarter. Earnings per share were $−0.21. The operating margin was 0.0%, 4.0 pp higher than a year earlier. — as of 5 August 2026.

What is Eastman Kodak Company's revenue?

Eastman Kodak Company reported revenue of $0.3 B in the Mar 26 quarter, +8.0% year on year. For the full FY25 fiscal year, revenue was $1.1 B (+2.9%). Over the last 4 years revenue compounded at −1.8% a year. — as of 5 August 2026.

What is Eastman Kodak Company's profit?

Eastman Kodak Company earned $−0.0 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−0.1 B. The operating margin ran 0.0% in the latest quarter. — as of 5 August 2026.

What is Eastman Kodak Company's market cap?

Eastman Kodak Company's market capitalisation is $1.0 B at a stock price of $8.9. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.

Does Eastman Kodak Company pay a dividend?

No — Eastman Kodak Company has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.

How is Eastman Kodak Company performing?

Eastman Kodak Company's latest readings are below. Against the S&P 500 it has been behind on a trailing-13-week view for 7 weeks. This describes what the data did, not a rating. — as of 5 August 2026.

What stage is Eastman Kodak Company in?

Deteriorating — profit and EPS growth are shrinking (profit growth −314.3% latest against +700.0% at its 12-quarter best), ROCE holding at 0.0%. The read comes from the last 12 quarters of growth (revenue growth +3.8% latest, profit growth −314.3% latest, eps growth −483.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.

Is Eastman Kodak Company beating the market?

Not lately — on a trailing-13-week view Eastman Kodak Company is currently behind the S&P 500 (7 weeks and counting; last ahead the week of 2026-06-18), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 1.1 years the stock moved +33% against the S&P 500's +24% — ahead of the index over the full window. — as of 5 August 2026.

Will Eastman Kodak Company's stock price go up?

This page publishes no price forecast for Eastman Kodak Company. What it measures instead: the stock price is $8.9. Direction is not something this site claims to know. — as of 5 August 2026.

Is the market betting against Eastman Kodak Company?

Somewhat — short interest is 9.6% of Eastman Kodak Company's tradable float, about 7.4 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.

Does Eastman Kodak Company have too much debt?

No — Eastman Kodak Company's debt-to-equity is 0.21. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 5 August 2026.

What is Eastman Kodak Company's capex?

Eastman Kodak Company spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.

What is Eastman Kodak Company's cash flow?

Eastman Kodak Company generated $0.5 B of operating cash flow in FY25 and $0.5 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $−0.1 B, so operating cash ran ahead of profit. — as of 5 August 2026.

Is Eastman Kodak Company's profit real cash?

Not fully — over the last 3 fiscal years, −45% of Eastman Kodak Company's reported profit arrived as operating cash. In FY25, operating cash was $0.5 B against reported profit of $−0.1 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.

How financially safe is Eastman Kodak Company?

On the balance sheet, the Z-score reads 1.31 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is inside the danger band — a real balance-sheet risk. — as of 5 August 2026.

Where is Eastman Kodak Company in its business cycle?

Eastman Kodak Company's FY25 operating margin was 0.0%, against a 5-year band of −4.3%–0.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 0.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.

What could break the Eastman Kodak Company story?

The sharpest disagreement: profits are rising, but only −45% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.

Is Eastman Kodak Company a stock worth studying right now?

This is not investment advice. The machine read: Eastman Kodak Company's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI